Ganesh Raghu

Professor Raghu received his medical degree in 1974 from Mysore Medical College ,University of Mysore, India, postdoctoral training in internal and chest medicine in the UK (Hartlepool General Hospital, affiliated with University of New Castle), residency in Internal medicine in USA (State University of New York at Buffalo, NY,) and fellowships in pulmonary diseases, critical care medicine and lung cell biology in USA ( University of Washington, Seattle). Dr. Raghu has had a longstanding clinical and scientific interest focused on pathogenesis, diagnosis and management of Interstitial lung diseases(ILD),idiopathic interstitial pneumonia (IIP), Hypersensitivity Pneumonitis , Sarcoid, Rheumatological lung diseases, and idiopathic pulmonary fibrosis (IPF) in particular. He is an international authority in these disorders. At the University of Washington(UW) Medical Center, he currently directs the University of Washington’s Center for ILD ( CILD) as well as directing the WASOG Center for Excellence for Sarcoidosis and Co- Director, Scleroderma clinic. He also served as the Director and Medical Director of the UW Lung transplant program that he initiated, developed and founded in 1991. Following the initiation and founding the UW’s Center for ILD in 2013, he stepped down his administrative and leadership roles of the UW lung transplant program but continues to be the transplant pulmonologist for his patients with ILD and remains an active member of the UW Lung transplant program. He serves/served on several national and international committees for management of ILD and IPF as well as in the National Institute of health (NIH,USA) lung biology and pathology study section on an adhoc basis and several leadership roles that include chairing and co chairing over 10 evidence based clinical practice guidelines for ILD and lung transplantation sponsored by ATS S-ERS-JRS-ALAT (American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Assoc.of Latin Am.Thoracic Society) and serving as an International Expert committee member in developing official documents on classification of interstitial pneumonias. He recently chaired a committee that included leading international experts in the field and representatives from NIH, patients and patient advocacy organization that led to the published 2024 report on endpoints for IPF clinical trials(AJRCCM). He has also served as an adhoc advisory panel member for the division of Pulmonary, Allergy and Rheumatology of the Food and Drug Administration FDA(USA) and also serves on the scientific advisory board for the Pulmonary fibrosis foundation, USA . He has just been appointed by the ATS to co chair an international expert committee to develop a living document for the management of all the major entities of interstitial pneumonia –a 2026 initiative by the ATS [Global Interstitial Lung Disease (GILD) Standards: Clinical Guidance from the American Thoracic Society] Dr. Raghu’s 40+ years of research is devoted to both basic science (lung fibroblast and extracellular matrix) and translational and clinical studies in the field of ILD, pulmonary fibrosis, IIP, and sarcoid. Having conducted several prospective clinical studies and trials in IPF and in pulmonary fibrosis associated with Scleroderma and sarcoidosis, he, along with other leading authorities, has provoked much awareness and interest for new treatment strategies based on the pathogenesis of pulmonary fibrosis. Among several research grants awarded to him and to his university from the NIH and the pharmaceutical industries to conduct IPF studies, he served in leadership roles in Clinical research network sponsored by the NIH – the IPFnet in USA and is an active and leading investigator of NIH funded ongoing clinical IPF trials besides serving leadership roles in the NIH studies and several industry sponsored clinical trials . Dr. Raghu has authored 425+ original articles, published in peer reviewed medical journals, and nearly 40 books/book chapters has altogether over 475 publications to date. He is among the “Highly cited Researchers” Essential Science Indicators (ESI) as Highly Cited Papers. *Clarivate Web of Science list (of the world’s population of scientists and scientists Highly Cited Researchers are 1 in 1000) in 2019, 2020, 2021 ,2022 and 2025. . He has served on editorial boards of several Respiratory Journals, currently serves on the editorial board of the European Respiratory journal, American Journal of Respiratory and Critical Care Medicine , as an advisory board member for The Lancet-Respiratory Medicine and is a frequent reviewer of manuscripts of original investigations submitted to many peer reviewed prestigious Respiratory journals AND journals for broad , general medical audience such as The New England Journal of Medicine, Lancet, and JAMA. Above all, he is a longstanding patient advocate and actively sees and manages patients with ILD every week at the UW’s Center for ILD, Seattle, WA, USA. He has been listed among the top 100 best doctors every year in USA( Castle Conolly) and Seattle’s best doctors since 2000. He holds an “Endowed Professorship Supporting Patients with Interstitial Lung Disease in Honor of Ganesh Raghu, MD”. He founded a pulmonary fibrosis support and education group in the Pacific northwest, USA in 1988, the first and the longest active group that meets every month at the UW Medical center and Dr Raghu attends this group meet